Bifogade filer
Magle Chemoswed Holding Q4, 2020
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Good quarter despite COVID impact provides strong year end
Magle Chemoswed today reports its year-end report for 2020.
“Despite the challenges and uncertainty brought about by the global COVID pandemic, I am pleased to report that, for Magle Chemoswed, it was a year of positives amongst the challenges. Our revenues increased year on year by 8%, and we ended 2020 with an EBIDTA of 12% compared with 9% in 2019. We achieved SEK 146,2 million in revenues in 2020 compared with SEK 139,4 million in 2019 showing the underlying strength of the business and the uptick in demand for the products and services that we are offering,” remarked Justin Pierce, CEO of Magle Chemoswed.
October-December 2020
- EBITDA equalled SEK 2,8 million (16,4).
- Operating profit (EBIT) is SEK 0,19 million (10,5)
- Net sales in the period amounted to SEK 35,9 million (48,4) a decrease of 26% on the same period last year.
- Profit after tax amounted to SEK -0,691 million (8,6)
- Earnings per share amounted to SEK -0,07 (17 287) per share
Full Year 2020
- Net sales amounted to SEK 137,7 million (127,5) an increase of 8% on the same period in 2019.
- EBITDA equalled SEK 16.1 million (13,3).
- Operating profit (EBIT) is SEK 4,5 million (0,1)
- Profit after tax amounted to SEK 1,8 million (0,7)
- Earnings per share amounted to SEK 0,24 (1 494) per share
Key events during the fourth quarter
- Magle Chemoswed entered into a binding purchase agreement with PharmaCept GmbH
Key events after the end of the fourth quarter
- Magle Chemoswed announced the CE certification of two medical device products based on the Company’s technology platform.
- Magle Chemoswed completed a directed share issue in January 2021